Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Approximately“
Suchtreffer
Begriffe & Kennungen
Gobivaz · 4.8 · 101 varies (approximately 2 years for 50 mg dose, approximately 3 years for 100 mg dose) as patients may have
Eintrag öffnenGobivaz · 4.8 · 44 In the controlled periods of pivotal trials and through approximately 4 years of follow-up, the incidence o
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGotenfia · 4.8 · 13 varies (approximately 2 years for 50 mg dose, approximately 3 years for 100 mg dose) as patients may have s
Eintrag öffnenGotenfia · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGotenfia · 4.8 · Malignancies other than lymphoma In the controlled periods of pivotal trials and through approximately 4 years
Eintrag öffnenGotenfia · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGotenfia · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenHerceptin · 4.8 · It is estimated that approximately 40 % of patients who are treated with Herceptin will experience some form o
Eintrag öffnenHerwenda · 4.8 · It is estimated that approximately 40% of patients who are treated with trastuzumab will experience some form
Eintrag öffnenHerzuma · 4.8 · It is estimated that approximately 40% of patients who are treated with trastuzumab will experience some form
Eintrag öffnenHetlioz · 4.5 · Smoking (moderate CYP1A2 inducer) Tasimelteon exposure decreased by approximately 40% in smokers compared to n
Eintrag öffnenHetlioz · 4.5 · Strong CYP3A4 inhibitors (e.g. ketoconazole) Tasimelteon exposure was increased by approximately 50% when co-a
Eintrag öffnenHycamtin · 4.8 · Fatigue was observed in approximately 25% and asthenia in 16% of patients receiving topotecan. Severe (Grade 3
Eintrag öffnen